Sugi Predict

Sugi Predict / Targets / PBK

PBK

Lymphokine-activated killer T-cell-originated protein kinase · Q96KB5 · PBK on Sugi Atlas →

15,969 patent compounds predicted against PBK, 10,195 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL935955 SCHEMBL935955 0.41 6/20
SCHEMBL477374 SCHEMBL477374 0.46 5/20
SCHEMBL148965 SCHEMBL148965 0.43 5/20
SCHEMBL475548 SCHEMBL475548 0.43 5/20
SCHEMBL269455 SCHEMBL269455 0.49 4/20
SCHEMBL270577 SCHEMBL270577 0.49 4/20
SCHEMBL328092 SCHEMBL328092 0.43 4/20
SCHEMBL965984 SCHEMBL965984 0.40 4/20
SCHEMBL1046082 SCHEMBL1046082 0.65 3/20
SCHEMBL1046293 SCHEMBL1046293 0.63 3/20
SCHEMBL1044288 SCHEMBL1044288 0.63 3/20
SCHEMBL1043953 SCHEMBL1043953 0.61 3/20
SCHEMBL1044969 SCHEMBL1044969 0.60 3/20
SCHEMBL1045992 SCHEMBL1045992 0.60 3/20
SCHEMBL1044761 SCHEMBL1044761 0.58 3/20
SCHEMBL1043681 SCHEMBL1043681 0.57 3/20
SCHEMBL1042933 SCHEMBL1042933 0.57 3/20
SCHEMBL1043036 SCHEMBL1043036 0.57 3/20
SCHEMBL1043039 SCHEMBL1043039 0.57 3/20
SCHEMBL1044503 SCHEMBL1044503 0.57 3/20

Clinical trials — most relevant to PBK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Evaluation of Cytokine-induced Killer (CIK) Cells as Therapy or Adjuvant Treatment for Advanced HCC PHASE3UNKNOWN
Induced-T Cell Like NK Cells for B Cell Malignancies PHASE1/PHASE2UNKNOWN
Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant PHASE1/PHASE2UNKNOWN
Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor PHASE1/PHASE2UNKNOWN
Safety and Efficacy of γδ T Cell Against Gastric Cancer PHASE1/PHASE2UNKNOWN
Immune Cell Therapy for Advanced Solid Tumors PHASE1/PHASE2NOT_YET_RECRUITING
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors PHASE1/PHASE2RECRUITING
Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma PHASE2NOT_YET_RECRUITING
Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis PHASE1/PHASE2COMPLETED
Cytokine Induced Killer (CIK) Cells In Leukemia Patients PHASE2COMPLETED
Cytokine-induced Killer Study for Patients With Stage II Melanoma PHASE2NOT_YET_RECRUITING
Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers PHASE1/PHASE2UNKNOWN
Study of DC-CTL Combined With CIK for Advanced Solid Tumor PHASE1/PHASE2UNKNOWN
Immunotherapy Before and After Surgery PHASE2WITHDRAWN
The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting Activation of Tcells PHASE1UNKNOWN
Safety Study of Cord Blood-derived Cytokine-induced Killer Cells in Patients With Solid Tumor After Radical Resection PHASE1UNKNOWN
Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors PHASE1UNKNOWN
Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies PHASE1COMPLETED
This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile. PHASE1RECRUITING
Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHD PHASE1RECRUITING
Universal CNK-UT Therapy for Refractory aGVHD PHASE1RECRUITING
A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM) PHASE1COMPLETED
PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors PHASE1RECRUITING
An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer PHASE1COMPLETED
Neoantigen-expanded Autologous Immune Cell Therapy PHASE1UNKNOWN
Study of Allogeneic Anti-PSMA CAR-NK Cell for Metastatic Castration-Resistant Prostate Cancer EARLY_PHASE1RECRUITING
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies EARLY_PHASE1RECRUITING
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Allogeneic CAR-NK Cell Therapy for Metastatic Castration-resistant Prostate Cancer (mCRPC) EARLY_PHASE1RECRUITING
RT201(Tumor Antigen-specific Macrophage Tumor Vaccine) nanUNKNOWN
A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PBK binder may also engage these)

ProteinNameSimilarity
Q9JJ78 — 0.999 Q9JJ78 →
Q6DHU8 — 0.986 Q6DHU8 →
Q8QZR7 — 0.966 Q8QZR7 →
Q5RER6 — 0.964 Q5RER6 →
Q8N165 — 0.963 Q8N165 →
Q6NU47 — 0.961 Q6NU47 →
Q9FGB1 — 0.960 Q9FGB1 →
Q6NU98 — 0.958 Q6NU98 →
CHEK1 Serine/threonine-protein kinase Chk1 0.958 landscape →
Q32PP3 — 0.957 Q32PP3 →
Q91ZN7 — 0.954 Q91ZN7 →
O35280 — 0.953 O35280 →
Q90999 — 0.953 Q90999 →
P49187 — 0.952 P49187 →
Q9SSA4 — 0.952 Q9SSA4 →
P49186 — 0.949 P49186 →
MAPK8 Mitogen-activated protein kinase 8 0.949 landscape →
MAPKAPK5 MAP kinase-activated protein kinase 5 0.948 landscape →
O54992 — 0.948 O54992 →
P53666 — 0.948 P53666 →
O42099 — 0.947 O42099 →
Q61831 — 0.946 Q61831 →
MAPK9 Mitogen-activated protein kinase 9 0.946 landscape →
Q90327 — 0.946 Q90327 →
Q5RF15 — 0.946 Q5RF15 →
MAPK10 Mitogen-activated protein kinase 10 0.946 landscape →
Q90ZY4 — 0.945 Q90ZY4 →
LIMK2 LIM domain kinase 2 0.945 landscape →
Q5F361 — 0.945 Q5F361 →
P38438 — 0.945 P38438 →